A Vipep Pty Limited

Cephalon, Inc.

Teva Pharmaceuticals Australia Pty Ltd

Debra Tamvakis

Anthony Gerard Doyle

Adam Clarke

Matthew Pollard

Lynn Dorothy Poulton

George Kopsidas

Philip Anthony Jennings

Peter John Hudson

Fabio Turatti

Andrew James Pow

Michael P Wheatcroft

David Leong

Paul R Sanders

Paul Robert Sanders

The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.

Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases

Antibodies against TL1a and uses thereof

The present invention provides an isolated protein comprising an immunoglobulin variable region comprising at least two cysteine residues positioned within framework region (FR) 2 and/or at least two cysteine residues positioned within framework region (FR3), wherein if at least two of the cysteine residues in FR2 and/or FR3 are not conjugated to a compound then an intra-framework disulphide bond is capable of forming between the cysteine residues. Preferably the protein comprises an immunoglobulin heavy chain variable region (V) and an immunoglobulin light chain variable region (V), wherein at least one of the variable regions comprises the two cysteine residues. The present invention also provides conjugates of the protein and another compound.

Immuno-conjugates and methods for producing them

The present invention provides an isolated protein comprising an immunoglobulin variable region comprising at least two cysteine residues positioned within framework region 1 such that if at least two of the cysteine residues are not conjugated to another compound a disulphide bond forms between the cysteine residues. Preferably the protein comprises an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein at least one of the variable regions comprises the two cysteine residues. The present invention also provides a protein that binds to TAG72. The present invention also provides conjugates of the protein and another compound.

Growing community of inventors

Camberwell, Australia

Debra Tamvakis